sponsors both time and money.

Ariana analyzes multi-parametric data (biochemical, genomic, proteomic, genetic, metabolic, patient characteristics, etc.) to identify patient responders and reduce clinical and drug development risk. Their clincial data analysis service optimizes clinical trial inclusion/exclusion criteria, and minimizes the risk of adverse events, thus reducing recruitment costs while detecting hidden signals and working with incomplete data sets. Overall, they have a flawless track record of maximizing the value of clinical assets.

Their biomarker data analysis service also helps you develop robust biomarker signatures and find the best combinations in your data. They deliver the actionable information you need to support your development processes: they integrate and analyze multi-parametric data to provide you with the most relevant combinations of biomarkers and patient characteristics.

Their methodology is implemented via their innovative software platform KEM® (Knowledge Extraction and Management), a system uniquely conceived and developed here at Ariana Pharma, with strong collaboration with academic (Institut Pasteur, CNRS) and industry groups (GSK, Novartis, Pfizer, etc.). KEM® is an effective technology used across the life science industry, including organizations such as the FDA, that can accelerate the discovery and development process.